NCT03489863View on ClinicalTrials.gov

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

March 20, 2019

Study Completion Date

March 20, 2019

Conditions
Coronary Artery Disease
Interventions
DRUG

Prasugrel

Maintenance dose will be maintained for 10±3 days.

DRUG

Ticagrelor

Maintenance dose will be maintained for 10±3 days.

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
collaborator

Scott R. MacKenzie Foundation

OTHER

lead

University of Florida

OTHER

NCT03489863 - Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study | Biotech Hunter | Biotech Hunter